Royalty Pharma (RPRX) Research & Development (2019 - 2026)

Royalty Pharma has disclosed Research & Development across 8 years of filings, most recently posting $39.8 million for Q1 2026.

• Research & Development for Q1 2026 came in at $39.8 million, down 21.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $390.8 million (up 651.54% YoY), and the FY2025 annual result was $452.0 million, up 22500.0% from the prior year.
• Research & Development came in at $39.8 million for Q1 2026 at Royalty Pharma, down from $50.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $250.0 million in Q2 2025 to a low of $500000.0 in Q1 2023.
• The 5-year median for Research & Development is $25.5 million (2022), against an average of $39.6 million.
• Across the five-year window, Research & Development tumbled 99.5% in 2023 and surged 49900.0% in 2025, its largest moves.
• Royalty Pharma's Research & Development stood at $50.5 million in 2022, then tumbled by 99.01% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then soared by 10000.0% to $50.5 million in 2025, then fell by 21.19% to $39.8 million in 2026.
• The last three Research & Development figures came in at $39.8 million (Q1 2026), $50.5 million (Q4 2025), and $50.5 million (Q3 2025), per Business Quant data.